Soledad buys BCR 193.09: Its surgical specialty products include fixation devices and planted patches for hernia and other soft tissue repairs, as well as hemostats and surgical sealants.

Its oncology products cover a variety of apparatus used in the procedure and management of other diseases and numerous cancers and ailments. Its urology products contain fundamental urology drainage goods, urinary and fecal continence goods, urological specialization products and Targeted Temperature Direction products. Finally, Brean Capital restated a hold rating on shares of C R Bard in a research report on Thursday, July 23rd. Barclays raised their price objective on C R Bard from $175.00 to $185.00 and gave the stock an equal weight rating in a research report on Friday, April 24th. The ex-dividend date of this dividend was Thursday, July 16th.


Marguerite:
Equities analysts expect that C R Bard will post $9.08 earnings per share for the current fiscal year.

Shelia:
The firm earned $859.80 million during the quarter, compared to analyst estimates of $836.18 million.

Margaret:
The company reported $2.27 earnings per share for the quarter, topping the consensus estimate of $2.18 by $0.09. During the same period in the previous year, the company earned $2.06 earnings per share.

Regena:
Thompson sold 1,200 shares of C R Bard stock in a transaction dated Friday, August 14th.

Deanna:
The long-term thesis remain intact but near term headwinds remain.

Chantel:
The DXY (US dollar index) is already up more than 7% year-to-date and this will impact their profitability.

Cathleen:
A significant portion of their revenue comes from European countries.

Belinda:
The increase in size of such medical institutions can lead to stronger bargaining power, which will compress the margins of TFX.

Dan:
This is because they can no longer afford to handle the patient load caused by the Act.

Dede:
Moving forward, I have projected an 80-100 basis points increase in their Gross margins mainly due to, 1) increasing demand for medical equipment in Asian countries and 2) newly launched products to derive higher ASP's.

C.R. Bard (NYSE:BCR)
//stockhand.net/us/?q=nyse%3Abcr&id=264301